Galera Therapeutics Company Description
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer.
The company’s lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC).
It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial.
The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | J. Sorensen |
Contact Details
Address: 101 Lindenwood Drive Malvern, Delaware 19355 United States | |
| Phone | 610 725 1500 |
| Website | galeratx.com |
Stock Details
| Ticker Symbol | GRTX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US36338D1081 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. J. Mel Sorensen M.D. | Chief Executive Officer, President and Chairman |
| Joel F. Sussman CMA, CPA | Chief Accounting Officer, Secretary and Treasurer |